Deborah Margaret Brown Buys 25,000 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Deborah Margaret Brown bought 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were acquired at an average cost of $0.85 per share, for a total transaction of $21,250.00. Following the purchase, the director directly owned 109,851 shares in the company, valued at $93,373.35. This trade represents a 29.46% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Oncolytics Biotech Price Performance

Shares of ONCY opened at $1.06 on Friday. Oncolytics Biotech Inc. has a 1 year low of $0.33 and a 1 year high of $1.51. The company has a 50 day simple moving average of $0.98 and a two-hundred day simple moving average of $1.07. The firm has a market cap of $112.51 million, a P/E ratio of -3.79 and a beta of 0.99.

Oncolytics Biotech (NASDAQ:ONCY) last released its earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. On average, sell-side analysts anticipate that Oncolytics Biotech Inc. will post -0.28 earnings per share for the current year.

Key Headlines Impacting Oncolytics Biotech

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Analyst Upgrades and Downgrades

Several research firms have commented on ONCY. Wall Street Zen downgraded shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. HC Wainwright increased their price target on Oncolytics Biotech from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ONCY. Citadel Advisors LLC bought a new stake in Oncolytics Biotech during the third quarter worth approximately $535,000. Seeds Investor LLC increased its position in shares of Oncolytics Biotech by 17.8% during the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock valued at $173,000 after purchasing an additional 33,826 shares during the last quarter. Tocqueville Asset Management L.P. purchased a new stake in Oncolytics Biotech during the 4th quarter valued at $63,000. CIBC Private Wealth Group LLC purchased a new stake in Oncolytics Biotech during the 4th quarter valued at $44,000. Finally, Ground Swell Capital LLC bought a new stake in Oncolytics Biotech in the fourth quarter worth $30,000. Hedge funds and other institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.